Craig Hallum started coverage on shares of Celcuity, Inc. (NASDAQ:CELC) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Shares of Celcuity (CELC) opened at 16.23 on Monday. The firm’s market capitalization is $157.79 million. The firm’s 50-day moving average is $13.75 and its 200 day moving average is $13.75. Celcuity has a 52 week low of $11.10 and a 52 week high of $16.50.
Celcuity Company Profile
Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.
Receive News & Ratings for Celcuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.